Improving the evaluation of new cancer treatments: Challenges and opportunities

Mace L. Rothenberg, David P. Carbone, David H. Johnson

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalNature Reviews Cancer
Volume3
Issue number4
StatePublished - Apr 2003

Fingerprint

Clinical Trials
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Improving the evaluation of new cancer treatments : Challenges and opportunities. / Rothenberg, Mace L.; Carbone, David P.; Johnson, David H.

In: Nature Reviews Cancer, Vol. 3, No. 4, 04.2003, p. 303-309.

Research output: Contribution to journalArticle

Rothenberg, Mace L. ; Carbone, David P. ; Johnson, David H. / Improving the evaluation of new cancer treatments : Challenges and opportunities. In: Nature Reviews Cancer. 2003 ; Vol. 3, No. 4. pp. 303-309.
@article{1628d6d9195243efbf537c6fa2b1fdaa,
title = "Improving the evaluation of new cancer treatments: Challenges and opportunities",
abstract = "There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?",
author = "Rothenberg, {Mace L.} and Carbone, {David P.} and Johnson, {David H.}",
year = "2003",
month = "4",
language = "English (US)",
volume = "3",
pages = "303--309",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Improving the evaluation of new cancer treatments

T2 - Challenges and opportunities

AU - Rothenberg, Mace L.

AU - Carbone, David P.

AU - Johnson, David H.

PY - 2003/4

Y1 - 2003/4

N2 - There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

AB - There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

UR - http://www.scopus.com/inward/record.url?scp=0037899935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037899935&partnerID=8YFLogxK

M3 - Article

C2 - 12671669

AN - SCOPUS:0037899935

VL - 3

SP - 303

EP - 309

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 4

ER -